Aniela Jakubowski
YOU?
Author Swipe
View article: Supplementary Table 1 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Supplementary Table 1 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors Open
Flow Cytometry Antibodies
View article: Data from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Data from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors Open
T-cell receptor (TCR)–modified T-cell therapies have shown promise against solid tumors, but overall therapeutic benefits have been modest due in part to suboptimal T-cell persistence and activation in vivo, alongside potential tumo…
View article: Supplementary Figures 1–20 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Supplementary Figures 1–20 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors Open
Supplementary Fig. S1: Design of a lymph node-targeted TCR-T cell therapy vaccine combination. Supplementary Fig. S2: Representative flowcytometric gating strategy. Supplementary Fig. S3: TCR-T therapy in irradiation pre-conditioned hosts …
View article: Supplementary Table 1 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Supplementary Table 1 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors Open
Flow Cytometry Antibodies
View article: Data from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Data from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors Open
T-cell receptor (TCR)–modified T-cell therapies have shown promise against solid tumors, but overall therapeutic benefits have been modest due in part to suboptimal T-cell persistence and activation in vivo, alongside potential tumo…
View article: Supplementary Figures 1–20 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Supplementary Figures 1–20 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors Open
Supplementary Fig. S1: Design of a lymph node-targeted TCR-T cell therapy vaccine combination. Supplementary Fig. S2: Representative flowcytometric gating strategy. Supplementary Fig. S3: TCR-T therapy in irradiation pre-conditioned hosts …
View article: Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors Open
T-cell receptor (TCR)–modified T-cell therapies have shown promise against solid tumors, but overall therapeutic benefits have been modest due in part to suboptimal T-cell persistence and activation in vivo, alongside potential tumor antig…
View article: 1339 Systemically administered onco-selective mRNA LNP achieves tumor regression and improves overall survival, as monotherapy
1339 Systemically administered onco-selective mRNA LNP achieves tumor regression and improves overall survival, as monotherapy Open
Background Checkpoint inhibition (CPI) therapies have led to large successes in treating certain cancer types, but they are largely ineffective in immunologically 'cold' tumors, with an immunosuppressive microenvironment. The immunosuppres…
View article: 827 Abstract withdrawn
827 Abstract withdrawn Open
Background Cancer immunotherapy has made significant advancements in revolutionizing cancer treatment, but the presence of T regulatory (Treg) cells within tumors presents a major hurdle. These cells can suppress the activation of effector…
View article: Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice
Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice Open
The recent emergence of a causal link between Epstein-Barr virus (EBV) and multiple sclerosis has generated considerable interest in the development of an effective vaccine against EBV. Here we describe a vaccine formulation based on a lym…
View article: Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates
Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates Open
View article: A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice
A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice Open
Recent emergence of a causal like between Epstein-Barr virus (EBV) and multiple sclerosis has generated considerable interest in the development of an effective vaccine against EBV. Here we describe a novel vaccine formulation based on a l…
View article: Programming the lymph node immune response with Amphiphile-CpG induces potent cellular and humoral immunity following COVID-19 subunit vaccination in mice and non-human primates
Programming the lymph node immune response with Amphiphile-CpG induces potent cellular and humoral immunity following COVID-19 subunit vaccination in mice and non-human primates Open
Despite the success of currently authorized vaccines for the reduction of severe COVID-19 disease risk, rapidly emerging viral variants continue to drive pandemic waves of infection, resulting in numerous global public health challenges. P…
View article: Lymph node-targeted vaccine boosting of TCR-T cell therapy enhances anti-tumor function and eradicates solid tumors
Lymph node-targeted vaccine boosting of TCR-T cell therapy enhances anti-tumor function and eradicates solid tumors Open
While T cell receptor (TCR)-modified T cell therapies have shown promise against solid tumors, overall therapeutic benefits in clinical practice have been modest due in part to suboptimal T cell persistence and activation in vivo, alongsid…
View article: A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2 Open
Lymph node–targeting adjuvant AMP-CpG enhances SARS-CoV-2 RBD vaccine-induced cellular and humoral immune responses.
View article: 479 A lymph-node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
479 A lymph-node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2 Open
Background The SARS-CoV-2 pandemic's public health, economic, and social impacts mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-C…
View article: A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2 Open
The SARS-CoV-2 pandemic has led to public health, economic, and social consequences that mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvan…
View article: Antibody-mediated targeting of TNFR2 activates CD8 <sup>+</sup> T cells in mice and promotes antitumor immunity
Antibody-mediated targeting of TNFR2 activates CD8 <sup>+</sup> T cells in mice and promotes antitumor immunity Open
Anti-TNFR2 antibodies induce costimulation of T cells, complete tumor regression, and immune memory in mice and can be combined with anti-PD1.